Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response.
- Francica P Institute of Animal Pathology, Vetsuisse Faculty, Länggassstrasse, University of Bern, 3012, Bern, Switzerland.
- Rottenberg S Institute of Animal Pathology, Vetsuisse Faculty, Länggassstrasse, University of Bern, 3012, Bern, Switzerland. sven.rottenberg@vetsuisse.unibe.ch.
- 2018-12-30
Published in:
- Genome medicine. - 2018
DNA Damage
DNA Repair
DNA, Neoplasm
Drug Resistance, Neoplasm
Humans
Neoplasms
Poly(ADP-ribose) Polymerase Inhibitors
English
Inhibitors of poly(ADP-ribose) polymerase (PARPi) have entered the clinic for the treatment of patients with cancers that lack homology-directed DNA repair, but drug resistance remains a clinical hurdle. Recent advances in the identification of PARPi resistance mechanisms have yielded a better understanding of DNA end protection and the relevance of endogenous poly(ADP-ribose) glycohydrolase, highlighting new vulnerabilities.
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.1186/s13073-018-0612-8
- PMID 30593284
- Persistent URL
- https://sonar.ch/global/documents/141322
Statistics
Document views: 48
File downloads:
- Full-text: 0